Freeze drying of peptide drugs self-associated with long-circulating, biocompatible and biodegradable sterically stabilized phospholipid nanomicelles

International Journal of Pharmaceutics

Volumn 356, Issue 1-2, 2008, Pages 345-350

  Lim, Sok Bee ^a   Rubinstein, Israel ^a,c   Önyüksel, Hayat ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b University of Illinois at Chicago   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Drug delivery; DSPE PEG2000; GIP; GLP 1; Nanobiotechnology; Nanocarrier; Nanomedicine; VIP

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N METHOXY POLY(ETHYLENE GLYCOL 2000); ETHYLENE DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; NANOCARRIER; NANOPARTICLE; PEPTIDE; PHOSPHOLIPID; VASOACTIVE INTESTINAL POLYPEPTIDE;

ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CIRCULAR DICHROISM; CIRCULATION; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; FLAME PHOTOMETRY; FLUORESCENCE SPECTROSCOPY; FREEZE DRYING; MICELLE; NANOBIOTECHNOLOGY; NANOMEDICINE; PARTICLE SIZE; PRIORITY JOURNAL; VISCOSITY;

DRUG STABILITY; FREEZE DRYING; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; MICELLES; NANOPARTICLES; PARTICLE SIZE; PEPTIDES; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; VASOACTIVE INTESTINAL PEPTIDE; VISCOSITY;

EID: 42649125562     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.01.014     Document Type: Article

References (19)

1. Drucker D.J., and Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 (2006) 1696-1705
2. Gandhi S., Tsueshita T., Önyüksel H., Chandiwala R., and Rubinstein I. Interactions of human secretin with sterically stabilized phospholipid micelles amplify peptide-induced vasodilation in vivo. Peptides 23 (2002) 1433-1439
3. Gautier J.F., Fetita S., Sobngwi E., and Salaun-Martin C. Biological actions of the incretins GIP and GLP-1(7-36) and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab. 31 (2005) 233-242
4. Groneberg D.A., Rabe K.F., and Fischer A. Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors. Eur. J. Pharmacol. 533 (2006) 182-194
5. Ishihara M., Fujita M., Obara K., Hattori H., Nakamura S., Nambu M., Kiyosawa T., Kanatani Y., Takase B., Kikuchi M., and Maehara T. Controlled releases of FGF-2 and paclitaxel from chitosan hydrogels and their subsequent effects on wound repair, angiogenesis, and tumor growth. Curr. Drug Deliv. 3 (2006) 351-358
6. Koo O.M., Rubinstein I., and Önyüksel H. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine. Nanomedicine 1 (2005) 77-84
7. Krishnadas A., Önyüksel H., and Rubinstein I. Interactions of VIP, secretin and PACAP(1-38) with phospholipids: a biological paradox revisited. Curr. Pharm. Des. 9 (2003) 1005-1012
8. Liang M.T., Davies N.M., Blanchfield J.T., and Toth I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv. 3 (2006) 379-388
9. Lim, S., Rubinstein, I., Önyüksel, H., 2007. Study of sterically stabilized phospholipid simple and mixed micelles as nanocarriers for peptide drugs. SFB 2007 Annual Meeting, Chicago, IL.
10. Lu Y., Yang J., and Sega E. Issues related to targeted delivery of proteins and peptides. AAPS J. 8 (2006) E466-E478
11. Menei P., Montero-Menei C., Venier M.C., and Benoit J.P. Drug delivery into the brain using poly(lactide-co-glycolide) microspheres. Expert Opin. Drug Deliv. 2 (2005) 363-376
12. Nauck M.A., Niedereichholz U., Ettler R., Holst J.J., Orskov C., Ritzel R., and Schmiegel W.H. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am. J. Physiol. 273 (1997) E981-E988
13. Önyüksel H., Ikezaki H., Patel M., Gao X.P., and Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm. Res. 16 (1999) 155-160
14. Önyüksel H., Sejourne F., Suzuki H., and Rubinstein I. Human VIP-alpha: a long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension. Peptides 27 (2006) 2271-2275
15. Sethi V., Önyüksel H., and Rubinstein I. Enhanced circulation half-life and reduced clearance of vasoactive intestinal peptide (VIP) loaded in sterically stabilized micelles (SSM) in mice with collage-induced arthritis (CIA). AAPS Pharmasci. 5 (2003) M1045
16. Sethi V., Önyüksel H., and Rubinstein I. A novel therapy for rheumatoid arthritis using α-helix VIP. FASED 2003 Conference Proceedings. San Diego, CA (2003) 660
17. Sreerama N., and Woody R. Poly (pro)II helices in globular proteins: identification and circular dichroic analysis. Biochemistry 33 (1994) 10022-10025
18. Tseushita T., Gandhi S., Önyüksel H., and Rubinstein I. Phospholipids modulate the biophysical properties and vasoactivity of PACAP-(1-38). J. Appl. Physiol. 93 (2002) 1377-1383
19. Ye M., Bhat G., Johnston K.A., Tan H., and Garnick M. Proprietary Rel-Ease drug delivery technology: opportunity for sustained delivery of peptides, proteins and small molecules. Expert Opin. Drug Deliv. 3 (2006) 663-675